Company: APAD
Filing Date: 2025-07-09
Form Type: S-1/A
Source: 0001213900-25-062242
Chunk: 94

Company: AParadise Acquisition Corp.
Filing Date: 2025-07-09
Form: S-1/A
Chunk 94
---
mate a business combination, may be materially adversely affected by any infectious disease outbreak and its continued effects and the status of debt and equity markets. Any significant outbreak of infectious diseases could result in an additional widespread health crisis that could adversely affect the economies and financial markets worldwide, and the business of any potential target business with which we consummate a business combination could be materially and adversely affected by the infectious disease outbreak. Furthermore, we may be unable to complete a business combination if there are any concerns relating to infectious diseases, such as travel restrictions, which can limit the ability to have meetings with potential investors or result in the target company’s personnel, vendors and services providers being unavailable to negotiate and consummate a transaction in a timely manner or even to conduct requisite due diligence. In addition, countries or supranational organizations in our target markets may develop and implement legislation that makes it more difficult or impossible for entities outside such countries or target markets to acquire or otherwise invest in companies or businesses deemed essential or otherwise vital. The extent to which 57 any infectious diseases may impact our search for a business combination will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity and new variants of infectious disease and the actions to contain such infectious disease or treat its impact, among others. The treatment or vaccine for any infectious diseases and any potentially emerging variants may be ineffective or underutilized. If the disruptions posed by infectious disease or other matters of global concern continue for an extended period of time, our ability to consummate a business combination, or the operations of a target business with which we ultimately consummate a business combination, may be materially adversely affected. In addition, our ability to consummate a transaction may be dependent on our ability to raise equity and debt financing which may be impacted by the outbreak of any infectious diseases and other events, including as a result of increased market volatility, decreased market liquidity and third -partyfinancing being unavailable on terms acceptable to us or at all. Finally, the outbreak of any infectious diseases may also have the effect of heightening many of the other risks described in this “Risk Factors” section. The requirement that we complete our initial business combination within the completion window may give potential target businesses leverage over us in negotiating a business combination and may limit the time we have in which to conduct due diligence on potential business combination targets, in particular as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce value for our shareholders. Any potential target business